Based on data from CREATE-X/JBCRG-04, would you consider adjuvant capecitabine in breast cancer patients treated with neoadjuvant chemotherapy who do not achieve a pCR?

Yes, 6-8 cycles of adjuvant capecitabine has been shown to improve survival in one randomized trial and therefore should be offered and disused with a patient. If capecitabine is given it could be given after surgery followed by radiation therapy or radiation may be completed first. Both options wer...

Interesting question. Those of us who were at this presentation at SABCS last week asked the authors about the pathologic CR rate prior to the capecitabine. They did not know the answer. If this rate was lower than expected, the benefit of the adjvuant xeloda may have been from the inadequate neoadj...